biostudies-literatureUnknown12Xu H<h4>Objective</h4>Most research reports on COVID-19 infections have focused on the correlation between the severity of the disease symptoms and immune deficits, while the mechanisms affecting the susceptibility to SARS-CoV-2 remain largely unknown. The study aimed to comprehensively analyze the differences in immunity, gut microbiota, metabolism, and proteomics between the SARS-CoV-2 resistant population and the susceptible population.<h4>Methods and results</h4>In this cohort comparison study, participants were rigorously selected based on inclusion and exclusion criteria in a continuous enrollment manner using combined questionnaires and clinical data, ultimately including 25 SARS-CoV-2 resistant volunteers versus 16 SARS-CoV-2 infected patients. The clinical information of the participaFrontiers in medicine1593007https://www.ebi.ac.uk/biostudies/studies/S-EPMC12277166biostudies-literatureBiological characteristics of SARS-CoV-2 resistant populations by integrated gut microbiota sequencing, metabolomics, and proteomics: a cohort comparison study.PMC12277166Li HChen YDeng LChen XXu HXu JXu YfalseBiological characteristics of SARS-CoV-2 resistant populations by integrated gut microbiota sequencing, metabolomics, and proteomics: a cohort comparison study.<h4>Objective</h4>Most research reports on COVID-19 infections have focused on the correlation between the severity of the disease symptoms and immune deficits, while the mechanisms affecting the susceptibility to SARS-CoV-2 remain largely unknown. The study aimed to comprehensively analyze the differences in immunity, gut microbiota, metabolism, and proteomics between the SARS-CoV-2 resistant population and the susceptible population.<h4>Methods and results</h4>In this cohort comparison study, participants were rigorously selected based on inclusion and exclusion criteria in a continuous enrollment manner using combined questionnaires and clinical data, ultimately including 25 SARS-CoV-2 resistant volunteers versus 16 SARS-CoV-2 infected patients. The clinical information of the participa2025-01-01T00:00:00Z20252025-08-24T03:05:18Z2025-08-24T03:05:18ZS-EPMC122771664069294710.3389/fmed.2025.1593007